PR Newswire·Sep 1, 2026, 8:01 AM ET

Bausch Health Announces Availability of Solta Medical's Fraxel FTX® in Australia

Bausch Health Companies Inc. & its aesthetics division Solta Medical announced the availability of Fraxel FTX in Australia starting September 1, 2026.
Fraxel FTX is the next-generation skin resurfacing platform designed to enhance treatment precision, workflow efficiency, & patient comfort.
The system utilizes two wavelengths: 1927 nm targets the epidermis, while 1550 nm penetrates the deeper dermis & epidermis.
Key features include Intelligent Optical Tracking™ with AccuTRAC® for uniform delivery, a redesigned ergonomic handpiece with 20% less weight, & integrated cooling routed through the handpiece.
The laser addresses five skin concerns: fine lines & wrinkles, lentigos & ephelides, acne & surgical scars, dyschromia including melasma, & actinic keratosis.
Solta Medical supports Australian practitioners with clinical education, practical training, & ongoing business support.
Contraindications include patients ineligible for general surgery, those with keloid predispositions, recent surgical changes, systemic steroid use, or current isotretinoin treatment.
Potential adverse events associated with the device include blistering, burns, skin discoloration, eye injury, infection, scarring, & delayed wound healing.
Fraxel FTX is an Rx-only device restricted to sale by or on the order of a physician under federal law.